Santa Monica, CA, United States of America

Stephan R Targan

This inventor holds 53 USPTO granted patents and 60 published patent applications and 11 EPO patents, primarily in Inflammatory Bowel Disease. Top assignees: Cedars-Sinai Medical Center, University of California, Prometheus Biosciences, Inc.. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephan R Targan. Retrieved from https://idiyas.com/inventor/stephan-r-targan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 53 (Patent Applications = 60)

% Patents Active = 92.5

EPO Patents = 11 (Patent Applications = 29)

Average Co-Inventor Count = 3.5

ph-index = 14

Forward Citations = 509(Granted Patents)

Forward Citations (Not Self Cited) = 272(Dec 10, 2025)

Location History:

Los Angeles, CA (US) (1997 - 2005)
Santa Monica, CA (US) (1999 - 2024)

Company Filing History:

50 out of 628

Cedars-Sinai Medical Center

patents

6 out of 16,058

University of California

patents

4 out of 15

Prometheus Biosciences, Inc.

patents

4. 2 out of 22

Prometheus Laboratories Inc.

Hitachi Chemical Company, Ltd.

patents

7. 1 out of 38

Hitachi Chemical Research Center, Inc.

patents

8. 1 out of 642

The UAB Research Foundation (The University of Alabama at Birmingham)

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Inflammatory Bowel Disease

TNF-like Ligand 1A

Anti-TNF Therapy

Transcriptomic Signatures

Microfluidic Devices

Genetic Variants

Crohn's Disease

Ulcerative Colitis

Anti-TL1A Antibodies

Fibrosis

Patient Selection

Nucleobases

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12618111 - METHODS OF DIAGNOSING INFLAMMATORY BOWEL DISEASE THROUGH RNASET2 (2026-05-05),

2. 12590160 - Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function (2026-03-31),

3. 12540358 - RNASET2 COMPOSITIONS AND METHODS OF TREATMENT THEREWITH (2026-02-03),

4. 12305236 - Methods and systems for selection and treatment of patients with inflammatory diseases (2025-05-20),

5. 12269873 - Signature of TL1A (TNFSF15) signaling pathway (2025-04-08),

6. 12264368 - Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures (2025-04-01),

7. 12110555 - Diagnosis and treatment of inflammatory bowel disease (2024-10-08),

8. 12084722 - Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease (2024-09-10),

9. 12018086 - Kit comprising contiguous nucleobases, including position 76, of RS5745994 (2024-06-25),

10. 11999789 - Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof (2024-06-04),

11. 11473061 - Systems and methods for growth of intestinal cells in microfluidic devices (2022-10-18),

12. 11440954 - Optimized anti-TL1A antibodies (2022-09-13),

13. 11434296 - Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function (2022-09-06),

14. 11312768 - Signature of TL1A (TNFSF15) signaling pathway (2022-04-26),

15. 11292848 - Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof (2022-04-05),

Title: **The Innovative Contributions of Stephan R. Targan**

Introduction

Stephan R. Targan is a prominent innovator based in Santa Monica, California, known for his groundbreaking work in the field of inflammatory bowel disease (IBD). With an impressive portfolio of 47 patents, Targan's inventions focus on diagnosing and treating conditions like Crohn's disease and ulcerative colitis, contributing significantly to advancements in medical science.

Latest Patents

Among Targan's latest patents, one noteworthy invention provides methods for the diagnosis and treatment of inflammatory bowel disease. This invention offers techniques for predicting susceptibility to IBD and its progression by identifying specific genetic variants, such as NOD2, TLR8, TLR2, CARD8, CARD15, and JAK3. Another embodiment outlines methods for evaluating the presence of certain anti-bacterial antibodies in individuals to aid in the diagnosis and management of IBD.

In addition, Targan's research delves into determining responsiveness to anti-TNFα therapy in individuals diagnosed with IBD. By assessing various risk factors, including genetic and serological markers, this work aims to optimize treatment strategies for better patient outcomes.

Career Highlights

Targan has held significant positions at esteemed institutions such as Cedars-Sinai Medical Center and the University of California. His experience in leading research initiatives has fostered innovative advancements in understanding and treating IBD, making him a key figure in the medical research community.

Collaborations

Throughout his career, Targan has collaborated with notable professionals in the field, including Jerome I. Rotter and Kent D. Taylor. These partnerships have further enriched his research, allowing for a comprehensive approach to tackling the complexities of inflammatory bowel disease.

Conclusion

Stephan R. Targan's dedicated efforts in the realm of medical innovation have made a lasting impact on the diagnosis and treatment of inflammatory bowel disease. His extensive patent portfolio not only reflects his inventiveness but also signifies a commitment to improving patient care through scientific advancements.

Profile summary based on public USPTO records.